

Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience


Dr. Riccardo Bomben Clinical and Experimental Onco-hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS

The authors declare no conflict of interest.






TP53 aberrations as prognostic and predictive markers in CLL






CLL cohort and methods



International Workshop on CLL 20-23 SEPTEMBER 2019 EDINBURGH




Results: 17p- deletion






Results: TP53 mutational status






Results: TP53 aberrations









Conclusions

1) 17p- impacted on OS only when detectable in more than 10% of nuclei;

- TP53 mutations conferred a significant shorter OS irrespectively of VAF percent;
- 3) Subclonal mutations should be considered for the identification of *TP53* mutated cases in a clinical setting.



Happy to answer to all your questions at the poster session



Acknowledgement

Clinical and Experimental Onco-Hematology Unit *Valter Gattei*

Tiziana D'Agaro Filippo Vit Tamara Bittolo Antonella Zucchetto Erika Tissino Federico Pozzo Dania Benedetti Elena Vendramini Mario Ballerini Pietro Bulian Francesca Rossi Massimo Degan Ilaria Cattarossi Eva Zaina Paola Nanni Hillarj Chivilò Michele Berton

Giovanni Del Poeta

S.Eugenio Hospital, University of Tor Vergata

Gianluca Gaidano Division of Hematology, University of Eastern Piedmont

Davide Rossi

Institute of Oncology Research and Oncology Institute of Southern Switzerland

Giovanni D'Arena Onco-Hematology Department, CRO-Basilicata

Francesco Di Raimondo Division of Hematology, University of Catania

Francesco Zaja Maggiore General Hospital, University of Trieste

Gabriele Pozzato Maggiore General Hospital, University of Trieste

Annalisa Chiarenza Ferrarotto Hospital, Catania, Italy











Happy to answer to all your questions at the poster session